MAN & SCIENCE is a company.
Key people at MAN & SCIENCE.
MAN & SCIENCE was founded by Robert Taub (Founder & chairman).
MAN & SCIENCE was founded by Robert Taub (Founder & chairman).
Man & Science is a Belgian private medical device company specializing in innovative, minimally invasive therapeutic solutions for severe headache disorders, including migraine and chronic cluster headache.[1][2][3] The company develops neurostimulation systems and image-guided precision injection technologies that enable outpatient procedures to interrupt nerve signals, reducing pain frequency and severity for patients who have not responded to conventional treatments.[2][3] Its portfolio targets a massive unmet need, as migraine affects 1 in 5 women and 1 in 15 men globally, with therapies like a battery-free occipital nerve field stimulation (ONFS) system implantable in 20 minutes and precision botulinum toxin injections in 15 minutes.[1][2]
In 2022, Man & Science expanded through the acquisition of Norway's Palion Medical, adding navigated injectable therapies for chronic migraine and cluster headache, complementing its neuromodulation offerings.[1] Key milestones include FDA Breakthrough Device Designation in 2021 for its ONFS system, accelerating U.S. market access for chronic cluster headache treatment.[3] Led by CEO Fabian Suarez and Chairman Robert Taub, the company emphasizes patient-centric, outpatient-driven innovations to restore normal, pain-free lives.[1][2]
Man & Science emerged as a Belgian medtech venture focused on headache disorders, though exact founding details are not specified in available records; its public milestones trace to at least 2021 with FDA interactions and 2022's Palion Medical acquisition.[1][3] Chairman Robert Taub has been instrumental as the "architect" of strategic moves like the Palion deal, highlighting his role in shaping the company's headache-focused portfolio.[1] The team comprises experienced scientists, engineers, clinical specialists, business experts, and serial entrepreneurs, actively recruiting for R&D, clinical, and QA roles.[2]
Growth accelerated via the 2022 acquisition of Palion Medical, spun out from Norway's University of Science & Technology, which brought precision injection tech for sphenopalatine ganglion targeting in awake patients.[1] This built on Man & Science's core neuromodulation work, earning FDA Breakthrough Designation for ONFS in chronic cluster headache—a pivotal validation of its early innovations.[3]
Man & Science rides the neuromodulation wave in medtech, addressing chronic pain—a market projected to grow amid rising neurological disorder prevalence like migraine (second most disabling condition globally).[2] Timing aligns with FDA's Breakthrough program push for expedited access to devices treating debilitating headaches, where traditional drugs often fall short.[3] Favorable forces include aging populations, demand for non-opioid outpatient therapies, and advances in image-guided navigation, positioning the company to disrupt a segment reliant on invasive implants or systemic meds.[1][2]
By consolidating assets like Palion, it influences the ecosystem through portfolio synergies, potentially setting standards for precision headache interventions and inspiring spinouts from academic hubs like NTNU.[1] This strengthens Europe's medtech footprint in U.S. markets via FDA priority review.
Man & Science is poised for U.S. commercialization of its ONFS system post-FDA Breakthrough, with Palion tech enabling broader migraine/cluster indications and pipeline expansions like injectable neurostimulation.[1][3] Trends like AI-enhanced navigation and non-invasive pain tech will amplify its edge, while partnerships or further M&A could scale global reach. Its influence may evolve from niche innovator to headache therapy leader, delivering outsized impact for underserved patients—turning innovative ideas into pain-free realities as promised.[2]
Key people at MAN & SCIENCE.
